Nervous Disorder TRIZ Cases

Adding a histidine amino acid to the redox motif sequence enhances peptide stability and specificity, reducing required dosages for immune modulation.

Combining baclofen, acamprosate, cinacalcet, mexiletine, sulfisoxazole, and torasemide improves cognitive function while minimizing side effects.

A pharmaceutical composition containing an aquaporin 4 function promoter enhances water transport through AQP 4 channels.

IL-3 signaling reprograms microglia to clear beta-amyloid and tau aggregates, resolving ineffective existing therapies for Alzheimer's disease.

Measuring maternal PZP concentrations identifies fetal intellectual disability risks before birth, eliminating diagnosis delays.

Compound 1 stabilizes transthyretin tetramers via optimized dosing, reducing amyloid fibril formation and improving heart function in patients.

Combines nicotinamide riboside with pterostilbene to boost NAD+ levels and activate sirtuin enzymes.

Stapled polypeptides use ring-closing metathesis to cross-link sidechains and stabilize alpha-helical structures.

A liquid food product manages the ketogenic diet using a balanced formulation of medium-chain triglycerides, fibers, and proteins.

Beta3 adrenergic receptor agonists activate latent hippocampal neural precursor cells to enhance self-renewal and multipotency.

Cometin protein acts as a neurotrophic growth factor to promote nerve regeneration and alleviate mechanical and cold hypersensitivity.

Formula I compounds modulate NMDA receptor activity to treat neuropathic pain while maintaining oral bioavailability.

A benzodiazepine derivative modulates serotonin receptors to treat schizophrenia symptoms.

Monoclonal antibodies targeting tau epitopes reduce aggregation and induce phagocytosis, addressing ineffective current treatments for Alzheimer's disease.

Silylation reagents facilitate scalable trofinetide synthesis, resolving commercial quantity bottlenecks in neurodegenerative disorder treatments.

1,3-propanedisulfonic acid resolves corticosteroid contradictions by reducing inflammatory mediators without adverse effects.

SkQ mitochondria-targeted antioxidants deliver neuroprotective effects via localized reactive oxygen species neutralization.

Brain-targeted rAAV9 vectors deliver glucocerebrosidase genes to resolve neurological refractoriness in Gaucher and Parkinson's disease patients.

Administering C1 esterase inhibitor blocks the contact activation system to protect tissues during reperfusion.

Assessing plasmablast levels before treatment avoids adverse reactions from ineffective interferon beta therapy while ensuring accurate patient selection.

Detecting AR mutations F877 and W742 enables patient stratification, preventing MDV3100 resistance through CDK4/6 inhibitor selection.

Poloxamer 188 prevents protein aggregation while polyols shield against oxidation, ensuring stable ready-to-use interferon therapy.

FGFR1 extracellular domain fusion molecules treat lung cancers with FGFR1 gene amplification, improving therapeutic responsiveness.

Segmentation of CD200+ leukocyte concentration, CD200R expression, and T cell ratios enables precise dosing schedules to overcome cancer immune evasion.

Optimized antibody variable regions improve blood-brain barrier penetration and reduce vasoconstrictive side effects.

Sonication induces beta-sheet formation in aqueous silk fibroin to produce porous microspheres without organic solvents that degrade therapeutic agents.

Antibodies bind Fn14 to block Tweak-induced NFκB signaling, addressing ineffective muscle wasting therapies.

Combines SAMe, methyl folate, and omega-3 fatty acids into a single therapeutic composition.

Merges AKBA-enriched Boswellia serrata extract with non-acidic resin to synergistically inhibit 5-lipoxygenase and reduce paw edema in arthritis models.

Beta-substituted amino acid derivatives exploit LAT1 transporters to selectively accumulate in cancer cells, reducing side effects from non-specific uptake.

Antibody molecules bind the phosphorylated Ser404 epitope of Tau protein to enable precise detection of pathological lesions.

Multimeric fusion proteins assemble into multimers to boost therapeutic effect while reducing adverse reactions from large IVIG doses.

Purifying Coibamide A via SPE and HPLC resolves the trade-off between high cytotoxicity against metastatic tumors and complex isolation efficiency.

Chlorotoxin-based CARs target glioblastoma independently of IL13Rα2, improving persistence and anti-tumor activity.

Differentiated ghMSCs restore neural stem cell proliferation while lowering amyloid beta toxicity in Alzheimer models.

Ginseng alcohol extract relieves sleep rhythm disorders and improves sleep quality without melatonin side effects.

Segmenting mesenchymal stem cell populations by miRNA profiles isolates specific therapeutic subpopulations, resolving unpredictable tumor promotion risks.

Anti-GCC antibody molecules bind specifically to target antigens on cancer cells.

Microencapsulated chewing gum manages addiction withdrawal by controlling cannabinoid and opioid release rates.

Adhesive layer with permeation enhancers boosts drug flux to bypass first-pass metabolism and eliminate quinidine co-administration.

An immobilized protease substrate degrades toxic proteins in cerebrospinal fluid, addressing inadequate removal of neurodegenerative agents.

Fusing IL-2 with IL-2Rα extracellular domains extends half-life, resolving short duration and high toxicity trade-offs.

Cyclizing a pentapeptide backbone and adding aromatic residues improves metabolic stability while maintaining strong inhibition of amyloid-beta aggregation.

Segments botulinum toxin into independent chains linked by disulfide bonds, reducing production complexity and safety risks.

Modified Fc regions in human anti-C5aR antibodies reduce phagocytosis and ADCC induction, resolving the trade-off between blocking efficacy and HAMA response.